Cargando…

Screening program for familial hyperchylomicronemia syndrome detection: Experience of a university health system

OBJECTIVE: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. MATERIALS AND METHODS: A cross-se...

Descripción completa

Detalles Bibliográficos
Autores principales: Masson, Walter, Barbagelata, Leandro, Fleitas, Milagros, Herzkovich, Nicole, Kerschner, Eliana, Rossi, Emiliano, Siniawski, Daniel, Ami, María V., Nogueira, Juan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247249/
https://www.ncbi.nlm.nih.gov/pubmed/36748937
http://dx.doi.org/10.20945/2359-3997000000601
Descripción
Sumario:OBJECTIVE: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. MATERIALS AND METHODS: A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages: (1) Review of electronic records and identification of suspected laboratory cases (triglyceride level ≥ 1,000 mg/dL); (2) Identification of suspected clinical cases (all suspected laboratory cases that had no relevant secondary factors) and application of the FCS score to define probable cases (score ≥ 10); (3) Perform genetic tests in probable cases. RESULTS: Globally, 348 suspected laboratory cases (mean age of 49.9 years, 77.3% men) were included. The median triglycerides level was 1,309 mg/dL (interquartile range 1,175-1,607 mg/dL). In total, 231 patients were categorized as suspected clinical cases. After applying the FCS score, 3% of them were classified as “very likely FCS” (probable cases). Four variants of uncertain significance have been identified. No previously reported pathogenic variants were detected. CONCLUSION: This study shows a screening program for the detection of FCS. Although no patient was diagnosed with FCS, we believe that more programs of these characteristics should be developed in our region, given the importance of early detection of this metabolic disorder.